COLO B Coloplast A/S Class B

Coloplast A/S - Coloplast completes the acquisition of Kerecis - Invitation for conference call on Monday, 4 September 2023 at 14.00-15.00 CEST

Coloplast A/S - Coloplast completes the acquisition of Kerecis - Invitation for conference call on Monday, 4 September 2023 at 14.00-15.00 CEST

Monday, 4 September 2023 at 14.00 – 15.00 CEST

In connection with the completion of the acquisition of Kerecis, Coloplast will host a conference call with Fertram Sigurjonsson, Founder and CEO of Kerecis.

A presentation will be available on Coloplast’s website before the conference call.

The webcast of the conference call will be available during and after the event.



Coloplast will be represented by:

Kristian Villumsen - President & CEO

Anders Lonning-Skovgaard - Executive Vice President, CFO

Fertram Sigurjonsson - Founder and CEO of Kerecis

Aleksandra Dimovska
- Senior Director, Investor Relations

Kristine Husted Munk - Senior Manager, Investor Relations



Webcast

Any participants who do not wish to actively participate in the question & answer session, please access the conference call as a webcast directly by clicking here: 



Dial-in details

For analysts and any participants wishing to actively participate in the question & answer session please sign up ahead of the conference call on the link below to receive an email with dial-in details: 

 

For more information, please contact:

Aleksandra Dimovska - Senior Director, IR. Tel.: / direct: . E-mail: Kristine Husted Munk - Senior Manager, IR. Tel.: / direct: . E-mail: Hannah K. Larsen - Coordinator & PA, IR. Tel.: / direct: . E-mail:  

Coloplast will be available on individual phone lines after the conference call for further questions.

Attachment



EN
01/09/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

 PRESS RELEASE

Coloplast udnævner Gavin Wood som ny CEO

Coloplast udnævner Gavin Wood som ny CEO Selskabsmeddelelse nr. 3/2026 Intern viden Coloplast udnævner Gavin Wood som ny CEO Det er med glæde, at Coloplasts bestyrelse kan annoncere udnævnelsen af Gavin Wood som ny CEO fra den 1. maj 2026. Gavin Wood afløser Lars Rasmussen, der har været midlertidig CEO siden den 5. maj 2025. Gavin Wood har i to årtier bestredet forskellige ledelsesroller i Johnson & Johnson, senest som øverste leder for Johnson & Johnson MedTech EMEA, en forretning der omsætter for adskillige milliarder dollars og har mere end 7000 medarbejdere på tværs af tre forretnin...

 PRESS RELEASE

Coloplast appoints Gavin Wood as new CEO

Coloplast appoints Gavin Wood as new CEO Announcement no. 3/2026 Inside information Coloplast appoints Gavin Wood as new CEO The Coloplast Board of Directors is pleased to announce the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-do...

 PRESS RELEASE

Coloplast A/S - Opdateret finanskalender 2025-26

Coloplast A/S - Opdateret finanskalender 2025-26 Venligst se vedlagte pdf.  Opdatering af datoer i finanskalenderen Coloplast har opdateret datoerne i selskabets finanskalender vedrørende offentliggørelsen af årsregnskabet for 2025/26 samt afholdelsen af den ordinære generalforsamling 2026. De opdaterede datoer er som følger: Årsregnskabsmeddelelse for 2025/26 og Årsrapport 2025/26: ændret fra 5. november 2026 til 3. november 2026Ordinær generalforsamling 2026: ændret fra 3. december 2026 til 1. december 2026 For yderligere information og kalenderinvitationer til kommende beg...

 PRESS RELEASE

Coloplast A/S - Updated Financial Calendar 2025-26

Coloplast A/S - Updated Financial Calendar 2025-26 Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual General Meeting 2026.  The updated dates are as follows: Financial Statements for the full year 2025/26 and Annual Report 2025/26: changed from November 5, 2026 to November 3, 2026Annual General Meeting 2026: changed from December 3, 2026 to December 1, 2026 For more information and calendar invitations for upcoming events, please visit:   Kind...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen

ResearchPool Subscriptions

Get the most out of your insights

Get in touch